The results strongly support a novel therapeutic action of PPAR-γ activators like troglitazone which might explain their beneficial effects PPAR-γ agonists in murine models of colitis [12,51] and in human ulcerative colitis [27]. Here, PPARG is linked to ulcerative colitis.